AstraZenecas new 2030 targets are bold attempt to reach for the stars, say analysts - Investing.com UK
| ZEG Stock | 124.55 0.05 0.04% |
Slightly above 61% of AstraZeneca PLC's investor base is looking to short. The analysis of current outlook of investing in AstraZeneca PLC suggests that many traders are alarmed regarding AstraZeneca PLC's prospects. AstraZeneca PLC's investing sentiment can be driven by a variety of factors including economic data, AstraZeneca PLC's earnings reports, geopolitical events, and overall market trends.
AstraZeneca |
AstraZenecas new 2030 targets are bold attempt to reach for the stars, say analysts Investing.com UK
Read at news.google.com
 |
AstraZeneca PLC Fundamental Analysis
We analyze AstraZeneca PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AstraZeneca PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AstraZeneca PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
AstraZeneca PLC is rated fifth in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
AstraZeneca PLC Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with AstraZeneca PLC stock to make a market-neutral strategy. Peer analysis of AstraZeneca PLC could also be used in its relative valuation, which is a method of valuing AstraZeneca PLC by comparing valuation metrics with similar companies.
Peers
AstraZeneca PLC Related Equities
| AMG | Amgen | 2.87 | ||||
| GIS | General Mills | 1.44 | ||||
| BAYN | Bayer AG | 0.37 | ||||
| ZEG | AstraZeneca PLC | 0.04 | ||||
| JNJ | Johnson Johnson | 0.13 | ||||
| IDP | Biogen | 0.67 |
Additional Tools for AstraZeneca Stock Analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.